Bicara Therapeutics Amends Public Offering to Include Pre-Funded Warrants for $150M Capital Raise

summarizeSummary

Bicara Therapeutics updated its public offering terms to include pre-funded warrants alongside common stock, aiming to raise $150 million to fund the development and potential commercial launch of its lead drug, ficerafusp alfa.

check_boxKey Events

• Public Offering Amended

  This FWP supplements the preliminary prospectus from February 24, 2026, to include pre-funded warrants as part of the $150 million public offering of common stock, with an option for an additional $22.5 million.

• Pre-Funded Warrants Introduced

  The company is offering pre-funded warrants to purchase common stock, primarily for investors who choose them in lieu of common stock. These warrants have a nominal exercise price of $0.0001 per share, do not expire, and are exercisable via cashless exercise.

• Strategic Use of Proceeds

  Net proceeds will be used to build medical and commercial infrastructure for a planned regulatory filing and commercial launch of ficerafusp alfa, accelerate its development, fund manufacturing, and support future indication expansion, following positive Phase 1b clinical data reported on February 19, 2026.

• Dilution Expected

  Purchasers of common stock or pre-funded warrants in this offering will experience immediate and substantial dilution in the book value of their investment.

auto_awesomeAnalysis

This Free Writing Prospectus (FWP) provides updated terms for the public offering announced yesterday, specifically introducing pre-funded warrants as an alternative to common stock for certain investors. The offering aims to raise $150 million, with an additional $22.5 million option for underwriters, which is a substantial capital raise for the company. The proceeds are earmarked for critical initiatives, including investing in medical and commercial infrastructure for a planned regulatory filing and commercial launch of ficerafusp alfa, accelerating its development, funding manufacturing, and supporting future indication expansion. This strategic financing follows recent positive Phase 1b clinical data for ficerafusp alfa, indicating the company is capitalizing on positive momentum to fund its pipeline. While the offering is dilutive to existing shareholders, securing significant capital is crucial for a life sciences company to advance its lead drug candidate towards commercialization. The pre-funded warrants, with a nominal exercise price and cashless exercise feature, are designed to attract investors who may have beneficial ownership limitations, facilitating the capital raise.